Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Social Networks
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers
  14. CDN Services

We began analyzing https://www.dovepress.com/biological-therapy-of-traditional-therapy-resistant-adult-onset-stills-peer-reviewed-fulltext-article-TCRM, but it redirected us to https://www.dovepress.com/biological-therapy-of-traditional-therapy-resistant-adult-onset-stills-peer-reviewed-fulltext-article-TCRM. The analysis below is for the second page.

Title[redir]:
Biological therapy of traditional therapy-resistant adult-onset Still' | TCRM
Description:
Biological therapy of traditional therapy-resistant adult-onset Still

Matching Content Categories {📚}

  • Health & Fitness
  • Science
  • Insurance

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🏙️ Massive Traffic: 50M - 100M visitors per month


Based on our best estimate, this website will receive around 76,004,851 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We can't figure out the monetization strategy.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Doi.org could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

patients, disease, aosd, stills, treatment, adultonset, refractory, anakinra, therapy, biological, efficacy, tocilizumab, rheumatol, articles, tnfα, biologics, safety, clin, review, published, received, case, drugs, mas, work, studies, adalimumab, infliximab, adult, press, medical, authors, study, etanercept, canakinumab, abatacept, therapies, remission, side, effects, reported, dove, treated, onset, macrophage, activation, syndrome, open, included, agents,

Topics {✒️}

including fast-track processing evidence-based review focuses life-threatening side effects life-threatening conditions dove medical press c-reactive protein level including high-dose corticosteroids nonsteroidal anti-inflammatory drugs anti-tnf-α agents manuscript login anti-tnf-α therapies traditional therapy-resistant adult-onset found tnf-α blockers favored authors disease-modifying antirheumatic drugs current clinical evidence published english-language articles macrophage activation syndrome case-based review c-reactive protein elevated cytokine level complete information reported adverse events biological agents targeting specific author tnf-α blockers anti-tnf-α enable stronger evidence anti-tnf switching serum cytokine profiles tnf-α favors tnf-α plays science core collection tnf-α inhibitors arthritis care res offer real benefits soft tissue abscess erythrocyte sedimentation rate activated t-cells acute-phase proteins high-dose steroids gonzalez-gay ma joint bone spine academic publishing division london sw1p 1wg uk vat group corticosteroid-sparing therapies main side effect initial manuscript draft completed manuscript revision

Questions {❓}

  • Is anti-TNF switching in refractory Still’s disease safe and effective?
  • May anakinra be used earlier in adult onset Still disease?
  • Why publish with us?

External Links {🔗}(123)

Analytics and Tracking {📊}

  • Google Analytics
  • Google Tag Manager
  • Google Universal Analytics

Libraries {📚}

  • jQuery
  • Video.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Com/cm/ef49a3f1-d8c1-47d6-88fc-50e41130631f/airgap

4.29s.